NEW STUDY BY BIOTRENDS HIGHLIGHTS CHANGES IN THE MANAGEMENT OF GOUT AND HYPERURICEMIA AMONG RHEUMATOLOGISTS AND PRIMARY CARE PHYSICIANS
STELARA IMPRESSES WITH EFFICACY DATA AND DOSING CONVENIENCE, BUT SAFETY CONCERNS LIKELY TO IMPACT NEAR TERM UPTAKE
Use of AMAG’s Feraheme is on the Rise with 23% of Nephrologists Reporting Use of the Product
New Report by BioTrends Research Group Will Explore the Perceptions and Expected Use of Alternative Dialysis Modalities in the US
DECISION RESOURCES, INC. ACQUIRES BIOTRENDS
Read more...
Page 6 of 17
